Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism

Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism - Impact of AT-III concentrates on PVT after splenectomy in liver cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002289

Enrollment

Registered

2009-08-03

Start date

2006-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cirrhotic patients who underwent laparoscopic splenectomy

Interventions

Cirrhotic patients who underwent laparoscopic splenectomy received an intravenous infusion of 1,500 units of AT-III concentrates over approximately 1 hour on post-operative day 1, 2, and 3.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cirrhotic patients who underwent laparoscopic splenectomy.

Exclusion criteria

Exclusion criteria: 1. Patients who had portal vein thrombosis before the operation. 2. Patients who had post-operative bleeding requiring hemostasis.

Design outcomes

Primary

Measure	Time frame
Comparison of the incidence of portal vein thrombosis between cirrhotic patients with or without AT-III concentrates	—

Countries

Japan

Contacts

Public ContactHirofumi Kawanaka

Kyushu University Hospital Department of Surgery and Science

harrykawa2002@yahoo.co.jp092-642-5466

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026